Fort Myers’ Mayor to Proclaim June as NeoGenomics’ Commitment to Cancer Month
13 Junio 2024 - 7:00AM
Business Wire
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing
services company, today announced that Fort Myers’ Mayor, Kevin
Anderson, will be dedicating June as NeoGenomics’ Commitment to
Cancer Month to honor cancer survivors and those currently living
with cancer. Headquartered in Fort Myers, NeoGenomics serves over
600,000 patients each year and is on a mission to serve one million
patients annually by 2028.
“With studies suggesting that 1 in 2 men and 1 in 3 women will
be diagnosed with cancer in their lifetime,1 our role as a leading
oncology testing services company is more crucial than ever,” said
Chris Smith, CEO at NeoGenomics. “Receiving this proclamation from
the mayor is a testament to the hard work and dedication of our
teammates in realizing our goals. At NeoGenomics, we strive to
deliver cancer testing options and information that empowers
providers to better diagnose and treat their patients.”
Mayor Anderson will formally announce the proclamation during
the City Council meeting on June 17. NeoGenomics’ CEO, Chris Smith,
will be in attendance to accept the honor and bring attention to
June as National Cancer Survivors Month. The declaration
acknowledges NeoGenomics’ commitment to supporting cancer patients
and survivors.
“The City of Fort Myers is thrilled to have NeoGenomics as a
community partner and industry leader in transforming care for
cancer patients, both internationally and right here in Southwest
Florida,” said Kevin Anderson, Mayor for the City of Fort Myers.
“We look forward to the proclamation this month and to recognizing
NeoGenomics’ contributions to supporting so many residents in our
region.”
The Mayor’s proclamation follows NeoGenomics’ signing of the
Working with Cancer Pledge, which showcases their dedication to
supporting team members who are living with cancer or caring for a
loved one with the disease. These initiatives show the company’s
dedication to fighting for and supporting those affected by
cancer.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and
information services, providing one of the most comprehensive
oncology-focused testing menus for physicians to help them diagnose
and treat cancer. The Company’s Advanced Diagnostic Division also
serves pharmaceutical clients in clinical trials and drug
development.
Headquartered in Fort Myers, FL, NeoGenomics operates CAP
accredited and CLIA certified laboratories for full-service sample
processing in Fort Myers, Florida; Aliso Viejo and San Diego,
California; Research Triangle Park, North Carolina; and Houston,
Texas; and a CAP accredited full-service, sample-processing
laboratory in Cambridge, United Kingdom. NeoGenomics also has
several, small, non-processing laboratory locations across the
United States for providing analysis services. NeoGenomics serves
the needs of pathologists, oncologists, academic centers, hospital
systems, pharmaceutical firms, integrated service delivery
networks, and managed care organizations throughout the United
States, and pharmaceutical firms in Europe and Asia.
Reference:
- National Cancer Institute,
https://www.cancer.gov/about-cancer/understanding/statistics
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240613164016/en/
For further information, please contact: NeoGenomics,
Inc. Investors: Kendra Sweeney kendra.sweeney@neogenomics.com
Media: Andrea Sampson Sampson Public Relations Group
asampson@sampsonprgroup.com
NeoGenomics (NASDAQ:NEO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
NeoGenomics (NASDAQ:NEO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024